Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03557229
Other study ID # ABC-18-19
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date July 23, 2018
Est. completion date June 2022

Study information

Verified date August 2021
Source American British Cowdray Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sepsis and septic shock are public health problems worldwide that represents an excessive cost for health systems. Despite the great technological and research advances, mortality can reach up to 80% in patients with multiple organ failure (FOM). Therapeutic studies focused on evaluating the usefulness of the use of antioxidants have shown different outcomes and results. This randomized clinical trial in patients with septic shock at two general intensive care units try to evaluate the usefulness of four different antioxidant therapies added to the conventional treatment, which includes: n-acetyl cysteine, vitamin C, vitamin E and melatonin. Measurement of parameters before and after treatment of oxidative stress includes nitrates and nitrites, lipid peroxidation, glutathione peroxidase, glutathione s transferase, extracellular activity of SOD, GSH concentration and evaluation of total antioxidant capacity. The investigators will also evaluate the clinical impact of antioxidant therapy with the SOFA score.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 131
Est. completion date June 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of septic shock in the last 24 hours characterized by refractory hypotension and vasopressor requirement despite sufficient fluid resuscitation (20 mL/kg of colloids or 40 mL/kg of crystalloids) to maintain a blood pressure = 65 mmHg with a lactate> 2 mmol/L. - Admitted to the ICU of the ABC Medical Center. - Give informed consent. Exclusion Criteria: - Patients who refuse to be included. - Chronic or recent use of steroids. - Use of statins. - Patients receiving some type of antioxidant treatment. - Any contraindication to the use of vitamin C, vitamin E, n-acetylcysteine or melatonin. - Pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Melatonin 5 mg
Oral: 50 mg once daily for 5 days
Vitamin C 1 GM Oral Tablet
Oral: 1 GM every 6 hours for 5 days
Vitamin E 400 UNT
Oral: 400 UNT every 8 hours for 5 days
N-acetylcysteine
Oral: 1200 mg every 12 hours for 5 days

Locations

Country Name City State
Mexico Centro Médico ABC Mexico City

Sponsors (1)

Lead Sponsor Collaborator
American British Cowdray Medical Center

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Other TNF-a Inflammatory Response Pathway Immediately before treatment and 48 hours after therapy
Other IL-1 Inflammatory Response Pathway Immediately before treatment and 48 hours after therapy
Other IL-6 Inflammatory Response Pathway Immediately before treatment and 48 hours after therapy
Other Ionized Ca2+ Electrolytes Immediately before treatment and 48 hours after therapy
Other Ionized Mg2+ Electrolytes Immediately before treatment and 48 hours after therapy
Primary Organic failure measurement by the Sequential Organ Failure Assessment Score (SOFA) The SOFA score is used to track a person's status during the stay in an intensive care unit (ICU) to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The worst physiological variables is collected serially every 24 hours of a patient's ICU admission. The "worst" measurement is defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24. The investigators are going to evaluate the daily total score and the trend before and after the administration of the therapy. Up to 7 days (1 week). From date of randomization and every 24 hours until discharge from the intensive care unit or date of death from any cause, whichever came first, assessed up to 7 days.
Secondary Nitrates and nitrites levels Oxidative stress Immediately before treatment and 48 hours after therapy
Secondary Malondialdehyde levels Lipid peroxidation Immediately before treatment and 48 hours after therapy
Secondary Total antioxidant capacity Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Glutathione Peroxidase Enzyme Activity Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Glutathione S-transferase Activity Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Extracellular Superoxide Dismutase Activity Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Glutathione concentration Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Selenium Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Vitamin C Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Thioredoxin Antioxidant status Immediately before treatment and 48 hours after therapy
Secondary Carbonylation Pro-oxidant status Immediately before treatment and 48 hours after therapy
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Completed NCT02306928 - PK Analysis of Piperacillin in Septic Shock Patients N/A
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2